February 22, 2016 –Endologix, Inc. filed a petition for inter partes review of multiple claims of LifePort Sciences, LLC’s patent. Endologix contended that the claims are unpatentable under 35 U.S.C. §§ 102 and 103 over prior art publications. The USPTO issued a decision on February 18, 2016 finding that the information presented in Endologix’s petition establishes a reasonable likelihood that Endologix will prevail in showing that several claims of LifePort Sciences’ patent are unpatentable. The USPTO has instituted an inter partes review on all of the claims at issue. The patent at issue is U.S. Patent No. 8,192,482, entitled “Endoluminal stent” and the claims at issue are claims 1-9, 12, 13, 21, 22, and 30.
The petition is pending in the United States Patent Trial and Appeal Board and is captioned: Petition for Inter Partes Review by Endologix, Inc., PTAB-IPR2015-01722.
By: David G. Varghese